U.S. markets open in 1 hour 35 minutes

Autolus Therapeutics plc (AUTL)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
2.83000.0000 (0.00%)
At close: 04:00PM EDT
2.6900 -0.14 (-4.95%)
After hours: 05:41PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close2.8300
Bid0.0000 x 1100
Ask0.0000 x 900
Day's Range2.7600 - 2.9584
52 Week Range1.9600 - 7.9000
Avg. Volume217,872
Market Cap257.304M
Beta (5Y Monthly)1.59
PE Ratio (TTM)N/A
EPS (TTM)-1.8420
Earnings DateMay 04, 2022 - May 09, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est15.06
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for AUTL

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Autolus Therapeutics plc
    Technical Assessment: Bearish in the Intermediate-TermMarket sentiment remains in the tank and the stock market simply cannot put together a decent rally. The National Association of Active Investment Managers (NAAIM) exposure index has fallen back to 20%, an extremely low equity exposure and a very bearish stance toward equities. This is the second time the index has dropped to 20% in the past six weeks. The seven-week average of exposure has fallen to 30%, the lowest since the pandemic low, as well as in 2015, 2011, and 2008/2009.
    Fair Value
    Economic Moat
    yesterdayArgus Research
View more
  • GlobeNewswire

    Autolus Therapeutics Presents Clinical Data Updates at the European Hematology Association Congress

    - AUTO4 shows high level of clinical activity with a novel targeting approach for patients with T Cell Lymphoma- AUTO1/22 demonstrates encouraging and durable responses in children ineligible for commercial CAR T product- Obe-cel shows high level of sustained clinical activity in B-NHL patients and first activity in Primary CNS Lymphoma Conference call to be held on Monday June 13, 2022 at 7:30 am EST/12:30 pm BST LONDON, June 10, 2022 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL),

  • GlobeNewswire

    Autolus to hold Annual General Meeting (AGM) of Shareholders on Tuesday, June 28, 2022

    LONDON, May 31, 2022 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today posted notice of its Annual General Meeting (AGM) to shareholders (the "Notice"), which can be viewed and downloaded from The AGM is scheduled to be held at The Studio, WestWorks, White City Place, London W12 7FQ on Tuesday, June 28, 2022, commencing at 8:00 a.m. BST. The business of the meeting

  • GlobeNewswire

    Autolus Therapeutics to Participate in the Jefferies Healthcare Conference, being held in New York from June 8 – 10, 2022

    LONDON, May 27, 2022 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announces that management will be attending the Jefferies Healthcare Conference at the Marriott Marquis in New York City. Autolus’ Chief Executive Officer Dr. Christian Itin will participate in a Fireside Chat on Thursday, June 9 at 9.00 – 9.30 am ET (2:00 pm – 2.30 pm BST) and the Company will also be attending